Clinical trials: Dengue
Dengue Fever
Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore
The purpose of this study is to assess the post-vaccination neutralizing antibody response against each dengue serotype by vaccine group.
- Trial name
- NCT02425098
- Testing
- Takeda's Tetravalent Dengue Vaccine Candidate (TDV), Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
- Where
- 3 sites in Singapore
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Takeda
Mass Screening
Dengue Virus NS1 Antigen (Bio-Rad) Clinical Protocol
The purpose of the study is to screen blood donors for the presence of NS1 antigen of the dengue virus at the American Red Cross in Puerto Rico region (and Monroe County, Florida) using the Platelia Dengue NS1 Ag enzyme…
- Trial name
- NCT01226173
- Testing
- Bio-Rad Platelia Dengue NS1 Ag test
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 182,353 people, healthy volunteers welcome
- Sponsor
- Bio-Rad Laboratories
Dengue Fever
A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06665035
- Testing
- TDV
- Where
- 4 sites in Colombia, Thailand
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue
The purpose of this study is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive TDV lots in healthy participants aged 18 to 60 years in non-endemic country(ies) for…
- Trial name
- NCT03423173
- Testing
- TAK-003
- Where
- 14 sites in United States
- Volunteers
- 923 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Disease, Dengue Virus
Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants…
- Trial name
- NCT05507450
- Testing
- V181 High-Potency Level, V181 Mid-Potency Level, V181 Low-Potency Level
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 1,271 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dengue
Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
Dengue viruses can cause dengue illness ranging from a mild illness to life-threatening disease. The purpose of this study is to evaluate the protective effectiveness of a dengue virus vaccine in healthy adults.
- Trial name
- NCT02021968
- Testing
- TetraVax-DV-TV003, rDEN2∆30-7169
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
A Study of INO-A002 in Healthy Dengue Virus-naive Adults
Phase 1, open label, single center, dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of dMAb-ZK190 following delivery of INO-A002 with Hylenex® recombinant delivered IM followed by EP in…
- Trial name
- NCT03831503
- Testing
- INO-A002, CELLECTRA® 2000, Dengue Fever Antibodies (IgG)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Dengue
Effectiveness of a Online Education Material to Improve Dengue Knowledge and Health-Seeking Intention
Dengue is an endemic infectious disease in Malaysia. Delays in seeking treatment and improper self-care contribute to dengue complications and mortality.
- Trial name
- NCT05661877
- Testing
- DengueAid mobile application, MyHealth website
- Where
- Malaysia
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Dengue, Dengue Vaccines
This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia
The purpose of this study is to describe the burden of DENV illness among household members aged 6 months to 50 years of selected communities in Latin America and Southeast Asia.
- Trial name
- NCT02766088
- Testing
- Blood sample collection
- Where
- 2 sites in Mexico, Philippines
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue
Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine
Infection with dengue viruses is the leading cause of hospitalization and death in children in many tropical Asian countries, and the development of a dengue vaccine is a top health priority.
- Trial name
- NCT02684383
- Testing
- rDEN3∆30
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
The purpose of this study is to assess the safety of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) (previously DENVax) in healthy adults when given as either a subcutaneous (SC) or intradermal (ID) injection at two dose…
- Trial name
- NCT01224639
- Testing
- TDV - Low Dose, TDV - High Dose
- Where
- Colombia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Inviragen Inc.
Dengue
A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
This descriptive study will evaluate the safety and immunogenicity of 5 different formulations of the WRAIR dengue vaccine compared to a placebo.
- Trial name
- NCT00239577
- Testing
- Live attenuated tetravalent dengue vaccine
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
Dengue viruses are widespread in most tropical and subtropical regions of the world. This study will evaluate the safety and protective efficacy of a dengue vaccine (called TV005) against viremia and rash induced by a DENV-2…
- Trial name
- NCT02317900
- Testing
- TV005, rDEN2∆30-7169
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Study of HBV-001 D1 in Healthy Adults
This is a single-center, double-blind, randomized, Phase 1 study to assess the safety and tolerability of HBV-001 D1 in healthy adult subjects.
- Trial name
- NCT00936429
- Testing
- DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hawaii Biotech, Inc.
Dengue
Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)
This study will determine whether at least one formulation of an experimental dengue vaccine (V180) is safe and causes an immune response.
- Trial name
- NCT01477580
- Testing
- Low-dose V180 with low-dose ISCOMATRIX™ adjuvant, Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant, Medium-dose V180 (non-adjuvanted)
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Travel-Related Illness, Malaria
Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
The investigators hypothesize that sex, age, area of exposure and purpose of travel are associated with different travel-related infections. The investigators also hypothesize that certain infections will have long-term sequelae.
- Conditions
- Travel-Related Illness, Malaria, Dengue, Chikungunya
- Trial name
- ITIT (NCT04672577)
- Testing
- Observational study
- Where
- Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Patricia Schlagenhauf
Dengue Vaccines
Passive Safety Surveillance Data of Dengue Vaccine, Qdenga (TAK 003) in Private Vaccination Sites in Buenos Aires, Argentina.
The TAK-003 vaccine, Qdenga, developed by Takeda, was approved by ANMAT in April 2023 and has been available in Argentina since November 2023 for individuals from 4 years old and without limit of age.
- Trial name
- NCT06898775
- Where
- Argentina
- Volunteers
- 112,345 people, healthy volunteers welcome
- Sponsor
- Fundación Vacunar
Dengue Vaccines
Retrospective Analysis of the Second Year of Safety Surveillance of the Qdenga® (TAK-003) Vaccine in Private Vaccination Centers, Including a Sub-analysis of Safety in Adults Over 60 Years of Age
The TAK-003 vaccine, Qdenga, developed by Takeda, was approved by ANMAT in April 2023 and has been available in Argentina since November 2023 for individuals aged 4 years and older, with no upper age limit.
- Trial name
- NCT07812142
- Testing
- Tak-003
- Where
- Argentina
- Volunteers
- 94,526 people, healthy volunteers welcome
- Sponsor
- Fundación Vacunar
Dengue
Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine
This is a randomized, multicenter, double-blind, placebo-controlled Phase III study that will evaluate efficacy and safety of a live attenuated, tetravalent, lyophilized dengue vaccine produced by Butantan Institute.
- Trial name
- NCT02406729
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 17 sites in Brazil
- Volunteers
- 16,935 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University